To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

December 30, 2022

Primary Completion Date

December 20, 2028

Study Completion Date

August 25, 2032

Conditions

Follicular Lymphoma ( FL)Marginal Zone Lymphoma (MZL)

Interventions

DRUG

parsaclisib

parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.

DRUG

rituximab

rituximab will be administered intravenously on select days as per protocol.

DRUG

obinutuzumab

obinutuzumab will be administered intravenously on select days as per protocol.